Skip to main content
. 2022 May 6;5(2):380–400. doi: 10.20517/cdr.2021.125

Figure 3.

Figure 3

Both KRAS and PTPN11 mutations confer Venetoclax resistance. KRAS mutation causes upregulation of MCL-1 and BCL2A1, while PTPN11 mutation causes upregulation of MCL-1 and BCL-xL. KRAS mutation also downregulates BCL-2 and BAX[37].